CANNABIDIVARIN (CBDV)

Among the dozens of minor cannabinoids being studied, very few have advanced to the level of human clinical trials. CBDV — cannabidivarin — is one of them. First isolated in 1969, it remained largely unstudied for decades before GW Pharmaceuticals (the maker of Epidiolex) identified it as a compelling anticonvulsant candidate. Since then, it has been the subject of multiple clinical trials and has emerged as one of the most rigorously investigated non-psychoactive cannabinoids outside of CBD itself.

What makes CBDV particularly interesting is not just what it shares with CBD — but where it diverges. Its shorter propyl side chain, distinct receptor interactions, and specific effects on brain excitation-inhibition balance give it a unique therapeutic identity that is increasingly well-defined by the science (Mannucci et al., 2021).

What Is CBDV?

Cannabidivarin (CBDV) is a naturally occurring minor phytocannabinoid in Cannabis sativa L. It was first isolated in 1969 by Vollner, Bieniek, and Korte. Structurally, it is the propyl (C3) homolog of CBD — meaning it has a three-carbon side chain where CBD has a five-carbon one. CBDV is the neutral form derived from cannabigenovarin (CBGV) via a biosynthetic pathway analogous to how CBD derives from CBG (Mannucci et al., 2021).

CBDV is found in higher concentrations in certain landrace cannabis strains — particularly indica-dominant varieties and strains native to Asia and Africa — and in CBD-rich hemp cultivars. It is also the acidic precursor molecule’s (CBDVA) decarboxylated neutral form.

CBDV vs. CBD: Key Differences

CBDV and CBD share the same terpenophenolic scaffold, non-psychoactive profile, and low CB1 receptor affinity. The key structural difference — a propyl vs. pentyl side chain — produces meaningful pharmacological distinctions, particularly in their effects on GABA systems, TRP channels, and brain excitatory-inhibitory balance (Mannucci et al., 2021).

How CBDV Works in the Body

CB2 Receptor Activity

Unlike CBD, which has minimal direct cannabinoid receptor activity, CBDV has shown demonstrable affinity and activity at CB2 receptors, with partial agonist behavior (Navarro et al., 2020; Zagzoog et al., 2020, as cited in Mannucci et al., 2021). CB2 receptors are expressed primarily in immune cells and peripheral tissues and play roles in inflammation and immune modulation.

TRPV Channel Activation

Like CBD, CBDV activates transient receptor potential vanilloid (TRPV) channels — particularly TRPV1 and TRPV2 — which are involved in pain signaling, inflammation, and neuronal excitability. TRPV1 activation followed by desensitization is thought to contribute to CBDV’s anticonvulsant effects by reducing neuronal excitability (Mannucci et al., 2021; Realm of Caring, 2023).

GABA Modulation

A 2016 study using human hippocampal tissue from drug-resistant epileptic patients found that CBDV reduced use-dependent GABA currents. GABA is the brain’s primary inhibitory neurotransmitter — disruptions in GABAergic signaling are central to many forms of epilepsy. CBDV’s effect on GABA receptor activity represents a potentially important anticonvulsant mechanism distinct from those of CBD (Rxleaf, 2020).

Brain Excitation-Inhibition Balance

A landmark 2019 magnetic resonance spectroscopy (MRS) study published in Translational Psychiatry directly measured CBDV’s effects on brain chemistry in humans. A single 600 mg oral dose of CBDV altered glutamate and GABA levels in the basal ganglia of both neurotypical adults and those with autism spectrum disorder — providing the first direct evidence in humans that CBDV modulates brain excitatory-inhibitory balance, a disruption implicated in ASD (Pretzsch et al., 2019).

What the Research Says

Strong Preclinical Evidence Anticonvulsant Activity

The first published evidence for CBDV’s anticonvulsant properties came from a 2012 study in the British Journal of Pharmacology, which found that CBDV significantly reduced multiple seizure types in rat models and completely prevented tonic-clonic convulsions. GW Pharmaceuticals subsequently reported that CBDV demonstrated “the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs” (Eir Health, 2025; Realm of Caring, 2023).

Moderate Evidence Autism Spectrum Disorder (ASD)

Preclinical evidence for CBDV’s effects on autism-like behaviors is substantial. A 2019 study published in Frontiers in Cell Neuroscience investigated the effect of CBDV on autism-like behaviors in mice, finding significant amelioration of social communication deficits, repetitive behaviors, and cognitive impairments. A companion study using a valproic acid prenatal exposure rat model — one of the most established ASD animal models — found CBDV treatment reversed ASD-like behaviors and restored hippocampal endocannabinoid system and glia alterations (Zamberletti et al., 2019).

The 2019 human MRS study by Pretzsch et al. added the first in-human evidence: a single CBDV dose altered brain glutamate levels in the basal ganglia of both ASD and neurotypical adults, with different response patterns between the groups — suggesting a mechanism relevant to the neurochemical differences observed in ASD.

Moderate Evidence Rett Syndrome

Rett syndrome is a rare neurodevelopmental disorder sharing features with ASD. Preclinical research has shown CBDV reduces motor impairments and cognitive deficits in Rett syndrome animal models — findings that helped fuel interest in CBDV’s broader neurodevelopmental therapeutic potential (Eir Health, 2025).

Emerging Evidence Gut Health and Inflammation

Preliminary research has also suggested CBDV may have benefits for gut health, potentially through its CB2 receptor activity and anti-inflammatory properties. This area is much earlier stage than the neurological applications (Realm of Caring, 2023).

Clinical Trials and Human Studies

CBDV is exceptional among minor cannabinoids for the depth of its clinical investigation. Key human studies include:

Pretzsch et al. (2019) — Published in Translational Psychiatry, this randomized single-dose crossover study used magnetic resonance spectroscopy to measure the effects of 600 mg CBDV on brain glutamate and GABA in 34 adults with and without ASD. It provided the first human neurochemical evidence of CBDV’s mechanism of action.

Patel et al. (2021) — A Phase 2 randomized controlled trial evaluating CBDV as add-on therapy in participants with inadequately controlled focal seizures, published in Epilepsy Research. This represents one of the most rigorous clinical evaluations of any minor cannabinoid to date.

Additional Phase 2 trials of CBDV in ASD and Rett syndrome have been registered and conducted, with GW Pharmaceuticals (now Jazz Pharmaceuticals, following acquisition) as the primary sponsor — lending pharmaceutical-grade rigor to the research (Eir Health, 2025).

Safety Profile

Across published clinical and preclinical studies, CBDV has demonstrated a favorable safety profile. In the Pretzsch et al. (2019) human study, participants experienced no ill or unintended effects following a single 600 mg dose. GW Pharmaceuticals has described CBDV as demonstrating significantly fewer side effects than currently approved antiepileptic drugs in preclinical models (Eir Health, 2025). As with all cannabinoids, potential drug-drug interactions via CYP enzyme pathways remain a clinical consideration that warrants further investigation.

Availability

CBDV is not available as a pharmaceutical product and is not specifically formulated in most commercial CBD products, though it naturally occurs as a minor component of full-spectrum hemp extracts — particularly those derived from high-CBD strains. It is available as an analytical reference standard (CAS 24274-48-4) for laboratory use. Consumer-facing CBDV-specific products exist in limited quantities from specialist suppliers, though none are FDA-regulated or clinically validated for consumer use.

Frequently Asked Questions

The Bottom Line

CBDV stands apart from the vast majority of minor cannabinoids by virtue of the depth of research that has been conducted on it. Its Phase 2 clinical trials in epilepsy and ASD, its human neuroimaging study showing direct brain chemistry effects, and its robust preclinical anticonvulsant profile put it in a genuinely different category from the many cannabinoids that exist only as compounds on a researcher’s shelf.

It is not yet an approved medicine, and translating Phase 2 signals into confirmed clinical efficacy requires further work. But of all the minor cannabinoids on the horizon, CBDV has the most scientifically credible case for eventually becoming the next FDA-approved cannabinoid drug after Epidiolex. The pharmaceutical investment, the mechanism data, and the early human evidence all point in the same direction — and that direction is worth watching closely.

Nothing in this article constitutes medical advice. Always consult a qualified healthcare provider before making any decisions about supplementation or treatment.

Back to List of Cannabinoids